Security National Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Security National Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-72	Closed	-$10K	–	470
2016 Q1	$10K	Hold	72	–	–	﹤0.01%	377
2015 Q4	$14K	Hold	72	–	–	0.01%	348
2015 Q3	$11K	Hold	72	–	–	﹤0.01%	371
2015 Q2	$13K	Hold	72	–	–	﹤0.01%	374
2015 Q1	$12K	Hold	72	–	–	﹤0.01%	390
2014 Q4	$13K	Buy	72 +47	+188%	+$8.71K	﹤0.01%	392
2014 Q3	$4K	Buy	+25	New	+$4.11K	﹤0.01%	484
2013 Q4	–	Sell	-13	Closed	-$2K	–	552
2013 Q3	$2K	Buy	+13	New	+$1.43K	﹤0.01%	501

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Security National Trust's ALXN Position: Q2 2016 in Review

Security National Trust sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 72 shares — an estimated $10K sold.

Security National Trust first reported a position in ALXN in Q3 2013 and held it in 8 quarters. The position peaked at $14K in Q4 2015. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

Security National Trust reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Security National Trust sold 72 Alexion Pharmaceuticals shares in Q2 2016, an estimated $10K.
Security National Trust first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 8 quarters.
Security National Trust's Alexion Pharmaceuticals position peaked at $14K in Q4 2015.
533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Security National Trust's 13F filing for Q2 2016, filed 22 Jul 2016.